Why is Akeso stock surging today?
Akeso stock experienced a significant surge of 14.5%, reaching HK$105.3, following AstraZeneca's announcement of a $2 billion strategic equity stake in Summit Therapeutics. The U.S.-based company holds overseas licensing rights to several Akeso treatments. This investment, structured as convertible preferred stock at an 18.6% premium to Summit's prior trading price, is viewed as a strong endorsement of ivonescimab's global potential and Akeso's role as the drug's originator and developer.
The positive sentiment extended to other innovative drug companies in the Hong Kong biotech sector, causing them to rally in response to the deal. This transaction further solidifies multinational pharmaceutical companies' increasing dedication to China-originated bispecific antibody therapies, bolstering Akeso's pipeline and out-licensing strategy.
Major institutions had already rated Akeso as a "Buy" in recent weeks, providing a favorable outlook as the catalyst unfolded. However, the broader Hong Kong market remained uncooperative, with the Hang Seng Index declining by 1% on the day.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
